Efficacy, Safety, and Cost-Effectiveness Analysis of Ceftazidime-Avibactam versus Polymyxin B in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections: A Target Trial Emulation.
{"title":"Efficacy, Safety, and Cost-Effectiveness Analysis of Ceftazidime-Avibactam versus Polymyxin B in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections: A Target Trial Emulation.","authors":"Na Hu, Fengjiao Xiao, Yechao Chen, Qiaoling Gu, Pei Liang, Yin Xu, Jinchun Liu, Yunxing Liu, Yi-Chen Li, Yinqiu Xu, Mengyin Liu, Dayu Chen, Haixia Zhang","doi":"10.1007/s40121-025-01164-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited, with polymyxin B (PMB) and ceftazidime-avibactam (CZA) being among the available choices. However, research on these options is scarce and significantly heterogeneous. This study aims to analyze the efficacy, safety, and cost-effectiveness of PMB and CZA within a standardized target trial emulation (TTE) framework.</p><p><strong>Methods: </strong>This retrospective study emulated a target trial to evaluate the efficacy, safety, and cost-effectiveness of CZA versus PMB for treating CRE infections. Conducted at Nanjing Drum Tower Hospital, this study included adult patients treated with CZA or PMB from July 2020 to December 2022. Data on demographics, treatment outcomes, and costs were collected. The primary outcomes included clinical cure, incidence of adverse drug reactions (ADRs), and cost-effectiveness. Secondary outcomes assessed 28-day all-cause mortality, microbiological eradication rates, incidence of acute kidney injury (AKI), and gastrointestinal events. The outcomes were assessed using the modified intention-to-treat (mITT) effects, per-protocol effects, and propensity score overlap weighting (PSOW) methods.</p><p><strong>Results: </strong>Between July 1, 2020, and December 31, 2022, 492 hospitalized patients treated with CZA or PMB were screened at Nanjing Drum Tower Hospital. Following inclusion and exclusion criteria, 176 patients were included in the mITT analysis, and 153 in the per-protocol analysis. The clinical cure rate was significantly higher in the CZA group compared to the PMB group across all analyses. The 28-day mortality was similar between groups, while the microbial eradication rate was significantly higher in the CZA group compared to the PMB group across all analyses. The incidence of ADRs was consistent between groups, but AKI occurred more frequently in PMB patients, while gastrointestinal events were more common in the CZA group. The CZA strategy demonstrated a 28.1% increase in efficacy, with an incremental cost-effectiveness ratio of 71,651.76 yuan. Sensitivity analyses confirmed the robustness of these findings.</p><p><strong>Conclusions: </strong>This study demonstrates that CZA has a higher clinical cure rate compared to PMB within a standard TTE framework. However, the overall incidence of ADRs was similar between the two treatments. Pharmacoeconomic analysis also indicated that CZA is cost-effective.</p><p><strong>Trial registration: </strong>https://www.chictr.org.cn ; identifier, ChiCTR2300067946.</p>","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-025-01164-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited, with polymyxin B (PMB) and ceftazidime-avibactam (CZA) being among the available choices. However, research on these options is scarce and significantly heterogeneous. This study aims to analyze the efficacy, safety, and cost-effectiveness of PMB and CZA within a standardized target trial emulation (TTE) framework.
Methods: This retrospective study emulated a target trial to evaluate the efficacy, safety, and cost-effectiveness of CZA versus PMB for treating CRE infections. Conducted at Nanjing Drum Tower Hospital, this study included adult patients treated with CZA or PMB from July 2020 to December 2022. Data on demographics, treatment outcomes, and costs were collected. The primary outcomes included clinical cure, incidence of adverse drug reactions (ADRs), and cost-effectiveness. Secondary outcomes assessed 28-day all-cause mortality, microbiological eradication rates, incidence of acute kidney injury (AKI), and gastrointestinal events. The outcomes were assessed using the modified intention-to-treat (mITT) effects, per-protocol effects, and propensity score overlap weighting (PSOW) methods.
Results: Between July 1, 2020, and December 31, 2022, 492 hospitalized patients treated with CZA or PMB were screened at Nanjing Drum Tower Hospital. Following inclusion and exclusion criteria, 176 patients were included in the mITT analysis, and 153 in the per-protocol analysis. The clinical cure rate was significantly higher in the CZA group compared to the PMB group across all analyses. The 28-day mortality was similar between groups, while the microbial eradication rate was significantly higher in the CZA group compared to the PMB group across all analyses. The incidence of ADRs was consistent between groups, but AKI occurred more frequently in PMB patients, while gastrointestinal events were more common in the CZA group. The CZA strategy demonstrated a 28.1% increase in efficacy, with an incremental cost-effectiveness ratio of 71,651.76 yuan. Sensitivity analyses confirmed the robustness of these findings.
Conclusions: This study demonstrates that CZA has a higher clinical cure rate compared to PMB within a standard TTE framework. However, the overall incidence of ADRs was similar between the two treatments. Pharmacoeconomic analysis also indicated that CZA is cost-effective.
期刊介绍：
Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
